Etoposide in leukemia, lymphoma and bone marrow transplantation

Leukemia Research

Volumn 13, Issue 8, 1989, Pages 639-650

  Stadtmauer, Edward A ^c   Cassileth, Peter A ^a   Gale, Robert Peter ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

bone marrow transplantation; Etoposide; leukemia; lymphoma; VP 16

Indexed keywords

AMSACRINE; AZACITIDINE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GALLIUM NITRATE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOGUAZONE; MITOXANTRONE; PREDNISONE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; ETOPOSIDE; HUMAN; LEUKEMIA; LYMPHOMA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024430614     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(89)90052-0     Document Type: Review

References (104)

1. Human anticancer effect of podophyllum derivatives (SPG and SPI)
2. Clinical studies with podophyllum compound SPI-77 and SPP-827
3. Symposium on etoposide (VP-16): current status and new developments
4. Etoposide (VP-16-213)
5. Effects of podophyllotoxin and VP-16-213 on microtubular assembly in vitro and nucleoside transport in HeLa cells
6. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemia lymphoblasts
7. Free radical scavengers inhibit VP-16 induced DNA damage and cytotoxicity
8. The activity of etoposide (VP-16) and teroposide (VM-26) agent human lung tumour cells in vitro: cytotoxicity and DNA breakage
9. DNA topoisomerase
10. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in Simian virus 40-infected monkey cells
11. Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage
12. Etoposide pharmacokinetics in patients with normal and abnormal organ function
13. Review of etoposide
14. Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene beta-d-glucopyranoside) by high pressure liquid chromatography
15. The clinical pharmacology of VM26 and VP16-213: a brief overview
16. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules
17. The pharmacokinetics of oral etoposide (VP-16-213)
18. Pharmacokinetics of a high-dose etoposide (VP-16-213) administered to cancer patients
19. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer
20. Etoposide (VP-16-213)
21. In-vivo experimental antitumor activity of etoposide
22. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors
23. In-vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia
24. Cischlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice
25. A phase I trial of continuous infusion VP16-213 (Etoposide)
26. High dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study
27. Epipodophyllotoxin VP16213 in treatment of acute leukaemias, haematosarcomas and solid tumors
28. Two epipodophyllotoxin derivatives VM 26 and VP 16213 in the treatment of leukemia, hematosarcomas and lymphomas
29. VP16-213 in acute myelogenous leukaemia
30. Phase II study of VP-16-213 in childhood malignant disease: a children's cancer study group report
31. A phase II trial of VP16-213 in adults with refractory acute myeloid leukemia
32. High-dose VP16-213 for the treatment of patients with previously treated acute leukemia
33. Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood
34. A clinical trial of the oral form of 4′demethyl-epipodophyllotoxin-beta-d-ethylideneglucoside VP-16-213
35. Etoposide in the treatment of acute leukemia in adults
36. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia
37. Phase II study of combination of chemotherapy with etoposide and amsacrine in relapsed adult leukemia
38. M-AMSA and VP-16 combinations in the treatment of acute myeloid leukemia
39. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia
40. Vinblastine, 5-azacytidine and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia
41. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine
42. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia
43. VP16-213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features
44. Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP16-213, vincristine and vinblastine (A-Triple-V)
45. Epipodophyllotoxin VP16-213 in acute non-lymphoblastic leukaemia
46. Amsacrine a review
47. A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia
48. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP-16-213
49. Combination of mitoxantron and etoposide in refractory acute myelogenous leukemia—an active and well tolerated regimen
50. Phase I–II trial of mitoxantrone in acute leukemia
51. Mitoxantrone in the treatment of relapsed and refractory acute leukemia
52. Rapid remission induction in adult acute non-lymphoblastic leukaemia
53. Etoposide in combination with cytarabine, doxorubicin and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age
54. Treatment of acute nonlymphocytic leukemia
55. A randomized trial of remission induction therapy intensified with VP-16 for acute nonlymphocytic leukemia (ANLL)
56. Epipodophyllotoxin (VP16-213) in the treatment of diffuse histiocytic lymphoma
57. Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma
58. Clinical trial of VP16-213 (NSC 141540) IV twice weekly in advanced neoplastic disease
59. Etoposide as a single agent in relapsed and advanced lymphomas: a phase II study
60. Phase I clinical trial of a new antitumor agent, 4′-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-d-glucopyranoside) (NSC-141540; VP-16-213)
61. Evaluation of VP-16-213 in malignant lymphoma and melanoma
62. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas
63. Cis-dichlorodiammine-platinum (II) (cis-platinum) and etoposide for patients with refractory lymphomas
64. Cis-dichlorodiammineplatimum (cis-platinum) and etoposide (VP-16) in malignant lymphoma—an effective salvage regimen
65. VP-16 in the treatment of malignant lymphomas: a report from the Swiss group for clinical cancer research (SAKK)
66. Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study
67. Cytarabine, cisplatin and etoposide chemotherapy for refractory non-Hodgkin's lymphoma
68. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin and prednisolone
69. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma
70. Salvage chemotherapy for lymphoma with VP-16, ifosfamide and cisplatin
71. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
72. Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma
73. Results of MIME salvage regimen for recurrent or refractory lymphoma
74. Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide and etoposide
75. Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas
76. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphoma
77. Vindesine, etoposide (VP-16) and prednisolone (VEP) in relapsed patients with grade II non-Hodgkin's lymphoma
78. Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate and etoposide
79. Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes
80. Etoposide, carmustine, bleomycin and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma
81. The podophyllotoxin derivates VP16-213 and VM26
82. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of PROMACE and MOPP chemotherapy
83. Third-line salvage chemotherapy in Hodgkin's disease
84. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide and prednimustine
85. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide and methotrexate
86. Lomustin, etoposide, vindesine, and dexamethasone (CEDV) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorwicin, bleomycin, vinblastine, and decarbazine (ABVD): a multicenter trial of the German Hodgkin study group
87. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
88. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia
89. Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases
90. The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia
91. Busulphan vs combination chemotherapy for initial treatment of chronic granulocytic leukemia
92. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213
93. Cyclophosphamide and VP16-213 with autologous bone marrow transplantation
94. Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors
95. High dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease
96. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies
97. High dose chemotherapy in conjunction with bone marrow transplantation for patients with refractory Hodgkin disease including use of two myeloablative potentially non-cross resistant chemotherapy regimens in sequence
98. Bone marrow transplantation (BMT) for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) utilizing total body irradiation (TBI), high-dose VP-16, and high-dose cyclophosphamide (CY): a phase I–II study
99. High dose cyclophosphamide (C), BCNU (B) and etoposide (V) with autologous bone marrow transplantation (ABMT) in relapsed Hodgkin's (HD) and non-Hodgkin's lymphoma (NHL): phase I trial
100. Bone marrow transplantation in acute leukaemia
101. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas and other malignancies
102. Podophyllotoxin derivative VP16-213
103. Etoposide: a semisynthetic epipodophyllotoxin